SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2026
Transbronchial needle core biopsy
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndobronchial ultrasound-guided transbronchial needle core biopsy (EBUS-TBNB) is an emerging technique designed to obtain histological specimens from mediastinal lesions. This meta-analysis aims to compare the performance of EBUS-TBNB
methodsA thorough search of the literature was performed across PubMed, Embase and Web of Science databases, covering the period from their inception through 1 October 2025. Diagnostic yields were pooled
results11 studies involving 1434 patients were analysed. The pooled diagnostic yield was 88.51% (678/766) for EBUS-TBNB and 80.11% (741/925) for EBUS-TBNA, with an odds ratio of 2.04 (95% CI 1.52-2.74; p<0.00001) and I
conclusionCurrent pooled evidence suggests a possible diagnostic advantage of EBUS-TBNB over EBUS-TBNA, particularly for lymphoma and sarcoidosis, with a similar safety profile. However, this apparent benefit should be interpreted cautiously given the limited randomised evidence, heterogeneity across needle platforms and substantial contribution of observational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.